AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Other Rare Disease medicines by Quarter
Other Rare Disease medicines — Europe product sales ($M) ($M)
AstraZeneca Other Rare Disease medicines: $20M in Q2 2026, up 11.1% from a year earlier.
Latest, Q2 2026
20
Period ended Jun 30, 2026
Change on a year earlier
+11.1%
18 in Q2 2025
History
6 quarters
Since Q1 2025
Sources
6
Documents cited below
Where the Q2 2026 figure comes from
“|| Other Rare Disease | | 74 | | 36 | | 33 | | 30 | | 8 | | 13 | | n/m | | n/m | | 20 | | 11 | | 5 | | 11 | | n/m | | n/m”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Rare Disease medicines — Europe product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 20 | +11.1% | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 20 | +25.0% | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 17 | – | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 16 | – | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 18 | – | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 16 | – | Form 6-K FY2025Q1 Earnings Release ↗ |
Breakdown
What makes up other Rare Disease medicines
Cite this data
StockData. (2026). AstraZeneca Other Rare Disease medicines ($M), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-other-rare-eu
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.